• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by ENDRA Life Sciences Inc.

    3/10/23 12:18:14 PM ET
    $NDRA
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $NDRA alert in real time by email
    SC 13G 1 ffsc13g.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENDRA LIFE SCIENCES, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 29273B02 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant* to which this Schedule is filed: [ x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) CUSIP No. 29273B02 1. Names of Reporting Persons. Michael Bryan, Sr. 2. Check the Appropriate Box if a Member of a Group (a) (b) 3. SEC Use Only 4. Citizenship or Place of Organization New Hampshire Number of Shares Beneficially Owned by Each Reporting Person With: 5. Sole Voting Power 192,500 6. Shared Voting Power 7. Sole Dispositive Power 192,500 8. Shared Dispositive Power 9. Aggregate Amount Beneficially Owned by Each Reporting * Person 192,500 10. Check if the Aggregate Amount in Row (9) Excludes * Certain Shares 11. Percent of Class Represented by Amount in Row (9) 6.1% 12. Type of Reporting Person IN ITEM 1. (a) Name of Issuer: ENDRA LIFE SCIENCES, INC. (b) Address of Issuer's Principal Executive Offices: 3600 Green Court, Suite 350 Ann Arbor, Michigan 48105 ITEM 2. (a) Name of Person Filing: Michael Bryan, Sr. (b) Address of Principal Business Office, or if None,* Residence: 51 Wentworth Rd Rye, NH 03870 (c) Citizenship: New Hampshire (d) Title of Class of Securities: Common Stock, $0.0001 par value per share (e) CUSIP Number: 29273B02 ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SS.240.13d-1(b)* OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A: (a)[_] Broker or dealer registered under Section 15 of the* Act (15 U.S.C. 78o). (b)[_] Bank as defined in Section 3(a)(6) of the Act (15* U.S.C. 78c). (c)[_] Insurance company as defined in Section 3(a)(19) of * the Act (15 U.S.C. 78c). (d)[_] Investment company registered under Section 8 of the* Investment Company Act of 1940 (15 U.S.C. 80a-8). (e)[_] An investment adviser in accordance with ss.240.13d-* 1(b)(1)(ii)(E); (f)[_] An employee benefit plan or endowment fund in* accordance with ss.240.13d-1(b)(1)(ii)(F); (g)[_] A parent holding company or control person in* accordance with ss.240.13d-1(b)(1)(ii)(G); (h)[_] A savings associations as defined in Section 3(b) of* the Federal Deposit Insurance Act (12 U.S.C. 1813); (i)[_] A church plan that is excluded from the definition of* an investment company under section 3(c)(14) of the Investment* Company Act of 1940 (15 U.S.C. 80a-3); (j)[_] Group, in accordance with ss.240.13d-1(b)(1)(ii)(J). ITEM 4. OWNERSHIP. (a) Amount beneficially owned: 192,500 (b) Percent of class: 6.1% (c) Number of shares as to which such person has: (i) Sole power to vote or to direct the vote 192,500 (ii) Shared power to vote or to direct the vote 0 (iii) Sole power to dispose or to direct the disposition of 192,500 (iv) Shared power to dispose or to direct the disposition of 0 ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS. If this statement is being filed to report the fact that as of * the date hereof the reporting person has ceased to be the * beneficial owner of more than five percent of the class of * securities, check the following [ ]. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF* OF ANOTHER PERSON. Not Applicable ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY * WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY * THE PARENT HOLDING COMPANY. Not Applicable ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE * GROUP. Not Applicable ITEM 9. NOTICE OF DISSOLUTION OF GROUP. ITEM 10. CERTIFICATIONS. By signing below, I certify that, to the best of my knowledge * and belief, the securities referred to above were acquired and * are held in the ordinary course of business and were not * acquired and not held for the purpose of or with the effect of * changing or influencing the control of the issuer of the * securities and were not acquired and are not held in * connection with or as a participant in any transaction having * such purpose or effect. SIGNATURE After reasonable inquiry and to the best of my knowledge and * belief, I certify that the information set forth in this * statement is true, complete and correct. March 9, 2023 (Date) /s/ Michael Bryan, Sr. (Signature) Michael Bryan, Sr./ Investor (Name/Title)
    Get the next $NDRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NDRA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $NDRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • ENDRA Life Sciences Provides a Business Update and Reports First Quarter 2025 Financial Results

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today provided a business update and reported financial results for the three months ended March 31, 2025. Business Update Incorporating Liver Diagnostics into the Management of Metabolic Disease ENDRA recently announced a strategic pivot to position the company to play an integral role in the treatment of metabolic disease. With a sharpened mission to transform the way steatotic liver disease (SLD) is diagnosed and managed, ENDRA is developing a revolutionary, low-cost, point-of-care diagnostic device—essentially a "blood pressure cuff" for the liver. This strategic shift is aimed squarel

      5/15/25 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Announces Enhanced Strategy to Enable the Early Detection and Management of Metabolic Diseases Facilitated by Emerging GLP-1 Therapies

      Enhanced strategic focus for TAEUS addresses a large, unmet global need for a cost-effective tool for monitoring liver health at the point of patient care ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today announced a new strategic direction to develop and deploy its TAEUS system as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs and other metabolic dysfunction-associated steatohepatitis (MASH) therapies. ENDRA's management has thoroughly evaluated the Company's technical capabilities and go-to-market strategy for TAEUS Liver and dete

      3/31/25 8:05:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: New insider Ubs Group Ag claimed ownership of 146,012 shares (SEC Form 3)

      3/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 2:47:08 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 4:01:26 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      6/14/24 8:00:02 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by ENDRA Life Sciences Inc.

      SC 13G - ENDRA Life Sciences Inc. (0001681682) (Subject)

      3/10/23 12:18:14 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: Market maker/broker-dealer Ubs Group Ag bought 0 shares (SEC Form 4)

      4/A - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      9/5/24 3:28:10 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Large owner Ubs Group Ag bought $2,052 worth of shares (3,715 units at $0.55) (SEC Form 4)

      4 - ENDRA Life Sciences Inc. (0001681682) (Issuer)

      8/29/24 4:30:01 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    SEC Filings

    See more
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/30/25 8:00:47 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 10-Q filed by ENDRA Life Sciences Inc.

      10-Q - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:59:32 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ENDRA Life Sciences Inc. (0001681682) (Filer)

      5/15/25 4:58:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Leadership Updates

    Live Leadership Updates

    See more
    • ENDRA Life Sciences Appoints Irina Pestrikova as Senior Director of Finance, Announces Departure of CFO David Wells

      ANN ARBOR, MI / ACCESSWIRE / June 15, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced the appointment of Irina Pestrikova as Senior Director of Finance and Principal Financial Officer. In this new position, Ms. Pestrikova will assume all day-to-day responsibilities previously performed by ENDRA's Chief Financial Officer David Wells, who will leave the Company effective June 18, 2021 to pursue another opportunity.Ms. Pestrikova has supported ENDRA since 2014 and has been actively involved in ENDRA's financial planning and analysis, accounting and SEC reporting functions. Previously, Ms. Pestrikova was a financial analyst at a

      6/15/21 8:35:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $NDRA
    Financials

    Live finance-specific insights

    See more
    • ENDRA Life Sciences Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides a Business Update

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo-Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the fourth quarter and full-year ended December 31, 2024, and provided a business update. Business Update ENDRA made significant progress against many of the new initiatives discussed during the Company's August 22, 2024, conference call to advance its TAEUS Liver device along the development and regulatory process. In addition, ENDRA separately announced today a revamped strategy for TAEUS as a biomarker solution for the early detection and management of metabolic diseases in patients being treated with glucagon-like peptide-1 (GLP-1) drugs. ENDRA's prog

      3/31/25 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement

      ENDRA Life Sciences Inc. (NASDAQ:NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC ("Nasdaq"). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listing. "Now that we have regained compliance with Nasdaq's listing requirements, we can focus all our efforts on making progress on our new transformational business strategies, which we reviewed during our August 22nd conference call,

      11/22/24 8:00:00 AM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • ENDRA Life Sciences Reschedules Second Quarter Conference Call to August 22, 2024

      ENDRA Life Sciences Inc. ("ENDRA") (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will host a conference call and webcast beginning at 4:30 p.m. Eastern time on August 22, 2024, to discuss quarterly results, provide an update on recent corporate developments and answer questions. This call was previously scheduled for August 14, 2024. The Company will file its quarterly report on form 10-Q with the SEC as regularly scheduled in the coming days. A press release summarizing its financial and operating results for the second quarter ending on June 30, 2024, will be issued on the day of the call. Participants are encouraged to pre-register

      8/13/24 4:05:00 PM ET
      $NDRA
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care